Olanzapine-based vs neurokinin-1 receptor antagonist antiemetic regimens in highly emetogenic chemotherapy: Systematic review and meta-analysis of efficacy and safety

Table 3 Quality assessment for randomized controlled trial, cohort and cross-sectional studies using the Newcastle Ottawa Scale

No.	Ref.	S1	S2	S3	S4	Comparability	E1/O1	E2/O2	E3/O3	Total
1	Maleki et al[1], 2020	1	1	1	1	1	1	1	1	8
2	Radhakrishnan et al[38], 2020	1	0	1	1	1	1	1	1	7
3	Wu et al[36], 2020	1	1	0	0	1	1	1	1	6
4	Sakai et al[17], 2021	1	1	1	1	1	1	1	0	7
5	Gao et al[10], 2022	1	1	1	1	1	1	0	1	7
6	Liu et al[39], 2022	1	1	1	1	2	1	1	1	9
7	Yip et al[18], 2023	1	1	1	1	2	1	1	1	9
8	Navari et al[9], 2023	1	1	1	1	1	1	1	1	8
9	Zhao et al[29], 2023	1	1	1	1	1	1	1	1	8
10	Inui et al[11], 2024	1	1	1	1	2	1	1	1	9
11	Ostwal et al[37], 2024	1	1	1	1	2	1	1	1	9
12	Shen et al[20], 2024	1	1	1	1	2	1	1	1	9
13	Bhargave et al[15], 2025	1	1	1	1	1	1	1	1	8
14	Attili et al[21], 2025	1	1	1	1	2	1	1	1	9

1: Denote the award of one point for the corresponding Newcastle-Ottawa Scale domain, while two asterisks. 2: Indicate two points awarded under the comparability domain, as per standard Newcastle-Ottawa Scale scoring guidelines. S: Selection; E: Exposure; O: Outcome.